Michael Hughes
@MSHughes_MD
Hematology-Oncology fellow at Columbia University, by way of Johns Hopkins Bayview and Harvard Medical School. Classics major. Thoughts/opinions my own.
#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. Simultaneous JCO pub, highlighted NY Times ascopubs.org/doi/10.1200/JC… nytimes.com/2025/06/03/hea…
In another multicenter (@columbiacancer and @BrighamWomens) study of BCMA BsAb in AL Amyloidosis (including stage IIIb), brisk and deep hematologic responses translating into organ responses, despite short follow-up! Now we need: Prospective data Long term follow up to test…
#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: pubmed.ncbi.nlm.nih.gov/40712156/. #mmsm
A splendid study by a dear friend and tremendous colleague! @MichaelMayMD @columbiacancer @DrGManji #ASCO25
Excited to present the updated clinical and translational results of our pilot study of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in untreated metastatic pancreatic cancer. @DrGManji @blabadieMD @PeterSARKO @columbiacancer
Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by @SLentzsch! #ASCO25 #MYELOMA #MRD @columbiacancer
To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: music.youtube.com/watch?v=iHockd… @columbiacancer
Another fun and enlightening ASCO with friends and colleagues @MSHughes_MD @KristineLacuna @Lindor_Q @columbiacancer
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint ir.prothena.com/investors/pres…
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis (15 patients from a collective database of >2000 patients @unipv & @columbiacancer)➡️Good organ response achievable after deep hematologic response, and lung transplant was feasible in one patient! Led by…
Brisk hematologic and cardiac organ response in a patient with Cardiac Monoclonal Immunoglobulin Deposition Disease treated with elranatamab! tinyurl.com/mt852vmn @DivayaB @SLentzsch @columbiacancer @CU_Cardiology
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma #mmsm @IMFmyeloma @theMMRF @HealthTree @LLSusa sanofi.com/en/media-room/…
Also congratulations to the one and only @AlexandraRojek for not one but TWO ASH abstract awards!!
@JCO_ASCO @charliecraddock @DrJFriedberg
JUST OU FOR #ASH24 and with a concomitant publication on JCO The GMMG-HD7 trial (NCT03617731) evaluated the addition of isatuximab (Isa) to the standard lenalidomide-bortezomib-dexamethasone (RVd) regimen in transplant-eligible patients with newly diagnosed multiple myeloma. In…
#ASH24 @MetBalev presenting important multi site real world data of tec -- excellent ORR and survival outcomes in a sicker than trial population! @rajshekharucms @SLentzsch @DivayaB @columbiacancer
#ASH24 sitting nearby @rajshekharucms -- the room was too packed with people learning from @SLentzsch, Dr Gertz of Mayo Clinic, and @vsanchorawala re modern treatments for AL amyloidosis!
